Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7295107 | 0.90 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL6207081 | 0.86 | AKR1B1 (0.91) | AKR1B1 | |
| SCHEMBL6207608 | 0.82 | AKR1B1 (0.91) | AKR1B1 | |
| SCHEMBL6205548 | 0.80 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL6206599 | 0.80 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL7126087 | 0.80 | AKR1B1 (0.64) | AKR1B1 | |
| SCHEMBL6206866 | 0.79 | AKR1B1 (0.75) | AKR1B1 | |
| SCHEMBL7126083 | 0.79 | AKR1B1 (0.60) | AKR1B1 | |
| SCHEMBL6207186 | 0.78 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL6205476 | 0.76 | AKR1B1 (1.00) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | claimed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | claimed |
| CN-1505514-A | Combination of aldose reductase inhibitors with cyclooxygenase-2 inhibitors | �Ʒ� | 2004-06-16 | — | — | CN | claimed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | claimed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | claimed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6872722-B2 | Therapies for tissue damage resulting from ischemia | PFIZER INC (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1260224-B1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | PFIZER PROD INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| CN-1505514-A | Combination of aldose reductase inhibitors with cyclooxygenase-2 inhibitors | �Ʒ� | 2004-06-16 | — | — | CN | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | MYLARI BANAVARA L (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1260224-A1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | AKR1B1 2/4885CYP1A2 250/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | AKR1B1 3/4885CYP1A2 259/4885 |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | TNNI3, TNNC1, TNNT2 | AKR1B1 2046/4885CYP1A2 4811/4885 |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | AKR1B1 3/4885CYP1A2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.